Industry Daily Summary
Industry Daily Summary: What Happened on October 28, 2026
Emcitate debuts as first US drug for MCT8 deficiency
Sensorion named Peter Weber chief medical officer, effective November 2.
Today in brief
Emcitate debuted as the first drug for patients with MCT8 deficiency in the United States.1
Peter Weber will become Sensorion’s chief medical officer on November 2.2
Also worth knowing
-
P
Sensorion said Weber has expertise in rare genetic ear disorders and has led gene-therapy development for genetic hearing loss. He oversaw inner-ear programs at Decibel Therapeutics and later consulted for Regeneron.2